Synovial sarcoma metastatic – Diagnostics – Overview of Information and Clinical Research

Diagnosing metastatic synovial sarcoma involves a combination of imaging studies, tissue sampling, and specialized genetic testing to confirm the presence and spread of this rare cancer. Because symptoms can resemble common joint problems and tumors grow slowly, accurate diagnosis often requires multiple steps and careful evaluation by specialists.

Introduction: Who Should Undergo Diagnostics

If you notice a lump under your skin that doesn’t go away, or if you experience unexplained swelling, pain, or numbness in your arms, legs, or near your joints, it’s important to see a healthcare provider as soon as possible. Synovial sarcoma can grow undetected for up to two years, and many people don’t have symptoms until the tumor becomes large enough to see or feel^[2]^[13]. Because this cancer can appear as a painless lump, it’s easy to overlook or mistake for something less serious.

You should seek diagnostic evaluation if you have a mass or swelling that persists, especially if it’s growing over time. Even though synovial sarcoma is rare—affecting only about 1,000 people each year in the United States—it’s most common in males under 30, though it can occur at any age^[1]^[13]. Early diagnosis matters greatly, as the outlook is more favorable when the entire tumor can be removed before it spreads to other parts of the body.

⚠️ Important

Symptoms of synovial sarcoma can look and feel like symptoms of other, less serious conditions such as arthritis, bursitis, or tendonitis. Because of this, the cancer may go undetected for a significant period. On average, it can take up to 2 years from the start of symptoms to diagnosis, which can increase the likelihood that the cancer has already advanced when it is eventually identified^[2]^[14].

People who already have a diagnosis of localized synovial sarcoma should also undergo regular monitoring, as this cancer has a high potential to spread, most commonly to the lungs and lymph nodes^[4]. If you’ve been treated for synovial sarcoma in the past, ongoing diagnostic surveillance helps detect any recurrence or metastasis early, when treatment options may be more effective.

Classic Diagnostic Methods

Diagnosing metastatic synovial sarcoma requires multiple types of tests. Your healthcare provider will start with a physical examination, asking about your symptoms and medical history. If they suspect synovial sarcoma, you’ll be referred to an oncologist—a doctor who specializes in cancer—for further testing^[2]^[13].

Imaging Tests

Imaging tests are essential to see where the tumor is located, how large it is, and whether it has spread to other areas of the body. These tests take pictures of the inside of your body using different technologies. The most commonly used imaging tests for synovial sarcoma include:

X-rays: These are often the first imaging test done. They can show bone involvement or help identify masses in soft tissue, though they provide limited detail compared to other imaging methods^[2]^[12].
Magnetic Resonance Imaging (MRI): An MRI uses magnets and radio waves to create detailed pictures of soft tissues like muscles, ligaments, and tendons. This test is particularly useful for synovial sarcoma because it shows the tumor’s exact size, depth, and relationship to surrounding structures such as nerves and blood vessels^[2]^[13].
Computed Tomography (CT) scans: A CT scan takes multiple X-ray images from different angles and uses a computer to create cross-sectional views of your body. CT scans are especially helpful for detecting whether the cancer has spread to the lungs, which is the most common site of metastasis^[2]^[12].
Ultrasound: This test uses sound waves to create real-time images of soft tissues. While less detailed than MRI or CT, ultrasound can help distinguish between solid masses and fluid-filled cysts^[2]^[13].

For metastatic disease, imaging of the chest is critical because about 50% of patients with high-grade soft tissue sarcomas eventually develop lung metastases, and in roughly 70% of those cases, the lungs remain the only site of spread^[18].

Biopsy

A biopsy is the definitive way to diagnose synovial sarcoma. During this procedure, your doctor removes a small sample of the tumor tissue for examination under a microscope. There are different ways to perform a biopsy:

Needle biopsy: A thin needle is inserted through the skin and into the tumor to extract a tissue sample. This is less invasive and can often be done in an outpatient setting^[2]^[12].
Surgical biopsy: Sometimes a larger tissue sample is needed, and a surgical procedure is performed to obtain it^[2]^[12].

The tissue sample is sent to a laboratory where a pathologist—a doctor who specializes in diagnosing diseases by examining tissues—studies the cells to determine if they are cancerous. Additional tests are performed on the biopsy sample to provide more detailed information about the cancer cells.

Genetic and Molecular Testing

Synovial sarcoma has a unique genetic signature that helps confirm the diagnosis. More than 90% of people with synovial sarcoma have a specific chromosomal translocation—a rearrangement of genetic material—between chromosomes X and 18^[1]^[8]. This translocation creates a fusion between the SS18 gene on chromosome 18 and one of several SSX genes on chromosome X, most commonly SSX1 or SSX2.

Doctors look for this genetic change to confirm that the tumor is indeed synovial sarcoma and not another type of soft tissue tumor. Detecting the SS18:SSX fusion proteins is considered a pathognomonic feature—meaning it’s uniquely characteristic of this disease and essential for establishing the diagnosis^[1]^[8]. Several molecular techniques, including specialized genetic tests, are used to identify this translocation.

Think of your chromosomes as instruction manuals for your cells, with genes as individual instructions. In synovial sarcoma, pieces of two different instruction manuals get mixed up and joined together incorrectly. This creates abnormal instructions that cause cells to behave like cancer cells^[2]^[13].

Diagnostics for Clinical Trial Qualification

If you’re considering participating in a clinical trial for metastatic synovial sarcoma, you’ll need to undergo specific diagnostic tests to determine if you’re eligible. Clinical trials test new treatments and often have strict criteria about who can enroll. The diagnostic requirements typically include:

Confirmation of Diagnosis

Clinical trials require documented proof that you have synovial sarcoma. This means you must have a biopsy that confirms the diagnosis, along with genetic testing showing the characteristic SS18:SSX fusion gene^[1]. Your healthcare provider will need to perform tests to verify this genetic marker is present in your tumor cells.

Disease Stage and Extent

Trials typically require comprehensive imaging to document the extent of metastatic disease. You’ll likely need recent CT scans of your chest, abdomen, and pelvis, along with MRI scans of the primary tumor site if it’s still present. These images help determine whether you meet the trial’s criteria regarding disease spread and measurable tumor size.

Blood Tests

Standard blood tests are performed to assess your overall health and ensure your organs are functioning well enough to tolerate the experimental treatment. These tests typically measure your kidney function, liver function, and blood cell counts. Your healthcare provider will do these tests to follow your progress and ensure it’s safe for you to participate^[2].

Performance Status

Clinical trials often require that participants be strong enough to undergo treatment. Doctors assess your ability to perform daily activities and care for yourself. This isn’t a specific test but rather an evaluation of how the disease affects your functioning.

Previous Treatment History

You’ll need to provide detailed records of any previous treatments you’ve received for synovial sarcoma, including surgery, radiation therapy, and chemotherapy. Many trials are specifically designed for patients whose disease has progressed after standard treatments, so this information determines your eligibility.

⚠️ Important

If you miss a scheduled appointment for blood collection or other required tests during a clinical trial, contact your healthcare provider as soon as possible to reschedule. Regular monitoring through blood tests and imaging is crucial not only for determining trial eligibility but also for tracking how well the treatment is working and identifying any side effects^[6].

Some newer trials may also require testing for specific biomarkers or proteins on tumor cells to see if you could be eligible for targeted therapies. For example, certain immunotherapy trials require testing to determine if your tumor cells express particular proteins that the treatment targets^[6].

Prognosis and Survival Rate

Prognosis

The outlook for someone with metastatic synovial sarcoma depends on many factors, and every person’s situation is different. Important factors that affect prognosis include where the tumor is located in your body, whether the cancer has spread to other parts of your body, how much of the tumor could be removed during surgery, the size of the tumor, how deep it is in the body, and your age^[7]^[22].

Tumors that are 5 centimeters or smaller tend to have a better prognosis than larger tumors. Similarly, tumors close to the surface of the body generally have a more favorable outlook than those growing deep within tissues. Synovial sarcomas of the arms, legs, or surface of the trunk usually have a better prognosis than those starting in other parts of the body^[22].

The grade of the tumor—which indicates how quickly cancer cells are growing and how likely they are to spread—also plays an important role. Low-grade synovial sarcomas are linked with better outcomes because they are less likely to spread or come back after treatment compared to high-grade tumors^[22].

If surgeons can completely remove the tumor with clear margins—meaning no cancer cells are found at the edges of the removed tissue—the prognosis is more favorable than when cancer cells remain after surgery. When surgery successfully removes all visible tumor and there is no sign of cancer elsewhere in the body, there is a greater chance of survival^[7].

People with metastatic synovial sarcoma generally face a more challenging outlook. The prognosis is particularly poor when the cancer has spread to other organs or when it has grown into bones, nerves, or blood vessels^[22]. People diagnosed under age 50 tend to have better outcomes than those over 50^[22].

Survival Rate

Patients with metastasized synovial sarcoma generally have a median survival of about 12 months, though some studies show improved median overall survival of 16 to 17 months after systemic treatment^[18]. However, it’s important to understand that survival rates are estimates based on how groups of people with similar conditions have done in the past, and they don’t predict what will happen in any individual case.

For synovial sarcoma in general, doctors estimate that anywhere from 36% to 76% of people will be alive five years after diagnosis. This wide range reflects the fact that outcomes vary greatly depending on many factors, including whether the disease was caught early or had already spread^[7]. Given that synovial sarcoma is so rare, survival rates may not be very accurate, and they don’t take into account newer treatments currently being developed.

When synovial sarcoma is diagnosed as metastatic disease—meaning it has already spread to other parts of the body—survival rates are lower. The five-year metastasis-free survival rate for patients who received chemotherapy in one study was 60%, compared to 48% for those who did not receive chemotherapy, though this was for patients with high-risk tumors larger than 5 centimeters^[9].

It’s crucial to remember that statistics represent averages across many people and cannot predict individual outcomes. Your own prognosis depends on the specific characteristics of your cancer, your overall health, how well you respond to treatment, and other personal factors. If you want information about your prognosis, talk to your doctor, who can consider all these factors together when discussing what to expect^[7].

#1 Clinical Trials Search in Europe